Divergent pathway of intestinal metaplasia and cystitis glandularis of the urinary bladder

Modern Pathology

Volumn 19, Issue 11, 2006, Pages 1395-1401

  Sung, Ming Tse ^a,b   Lopez Beltran, Antonio ^c   Eble, John N ^a   MacLennan, Gregory T ^d   Tan, Puay Hoon ^e   Montironi, Rodolfo ^f   Jones, Timothy D ^a   Ulbright, Thomas M ^a   Blair, Jean E ^d   Cheng, Liang ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c UNIVERSITY OF CÓRDOBA   (Spain)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e SINGAPORE GENERAL HOSPITAL   (Singapore)

^f UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

CDX2; Cystitis glandularis; Cytokeratin 20; Hepatocyte specific antigen; Intestinal metaplasia; Urinary bladder

Indexed keywords

ANTIGEN; CYTOKERATIN 20; CYTOKERATIN 7; HEPATOCYTE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR CDX2; UNCLASSIFIED DRUG;

ARTICLE; BLADDER; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; COLON MUCOSA; COMPARATIVE STUDY; CONTROLLED STUDY; CYSTITIS; GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE METAPLASIA; MORPHOLOGY; PATHOGENESIS; PRIORITY JOURNAL; STAINING;

AUTOANTIGENS; CELL TRANSFORMATION, NEOPLASTIC; CYSTITIS; HEPATOCYTES; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINES; KERATIN-20; KERATIN-7; METAPLASIA; PRECANCEROUS CONDITIONS; RETROSPECTIVE STUDIES; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 33750311873     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800670     Document Type: Article

References (47)

1. Bell TE, Wendel RG. Cystitis glandularis: benign or malignant? J Urol 1968;100:462-465.
2. Davies G, Castro JE. Cystitis glandularis. Urology 1977;10:128-129.
3. Murphy WM, Grignon DJ, Perlman EJ. Tumors of the Kidney, Bladder, and Related Urinary Structures. American Register of Pathology: Washington, DC, 2004.
4. Young RH, Bostwick DG. Florid cystitis glandularis of intestinal type with mucin extravasation: a mimic of adenocarcinoma. Am J Surg Pathol 1996;20:1462-1468.
5. Jacobs LB, Brooks JD, Epstein JI. Differentiation of colonic metaplasia from adenocarcinoma of urinary bladder. Hum Pathol 1997;28:1152-1157.
6. Bullock PS, Thoni DE, Murphy WM. The significance of colonic mucosa (intestinal metaplasia) involving the urinary tract. Cancer 1987;59:2086-2090.
7. Edwards PD, Hurm RA, Jaeschke WH. Conversion of cystitis glandularis to adenocarcinoma. J Urol 1972;108:568-570.
8. Lin JI, Yong HS, Tseng CH, et al. Diffuse cystitis glandularis. Associated with adenocarcinomatous change. Urology 1980;15:411-415.
9. Susmano D, Rubenstein AB, Dakin AR, et al. Cystitis glandularis and adenocarcinoma of the bladder. J Urol 1971;105:671-674.
10. Freund JN, Domon-Dell C, Kedinger M, et al. The Cdx-1 and Cdx-2 homeobox genes in the intestine. Biochem Cell Biol 1998;76:957-969.
11. James R, Erler T, Kazenwadel J. Structure of the murine homeobox gene cdx-2. Expression in embryonic and adult intestinal epithelium. J Biol Chem 1994;269:15229-15237.
12. Silberg DG, Swain GP, Suh ER, et al. Cdx1 and cdx2 expression during intestinal development. Gastroenterology 2000;119:961-971.
13. Suh E, Chen L, Taylor J, et al. A homeodomain protein related to caudal regulates intestine-specific gene transcription. Mol Cell Biol 1994;14:7340-7351.
14. Suh E, Traber PG. An intestine-specific homeobox gene regulates proliferation and differentiation. Mol Cell Biol 1996;16:619-625.
15. Almeida R, Silva E, Santos-Silva F, et al. Expression of intestine-specific transcription factors, CDX1 and CDX2, in intestinal metaplasia and gastric carcinomas. J Pathol 2003;199:36-40.
16. Chu PG, Schwarz RE, Lau SK, et al. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2. Am J Surg Pathol 2005;29:359-367.
17. De Lott LB, Morrison C, Suster S, et al. CDX2 is a useful marker of intestinal-type differentiation: a tissue micro-array-based study of 629 tumors from various sites. Arch Pathol Lab Med 2005;129:1100-1105.
18. Ko S, Chu K, Luk JM, et al. CDX2 co-localizes with liver-intestine cadherin in intestinal metaplasia and adenocarcinoma of the stomach. J Pathol 2005;205:615-622.
19. Rossi G, Murer B, Cavazza A, et al. Primary mucinous (so-called colloid) carcinomas of the lung: a clinicopathologic and immunohistochemical study with special reference to CDX-2 homeobox gene and MUC2 expression. Am J Surg Pathol 2004;28:442-452.
20. Werling RW, Yaziji H, Bacchi CE, et al. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol 2003;27:303-310.
21. Eda A, Osawa H, Satoh K, et al. Aberrant expression of CDX2 in Barrett's epithelium and inflammatory esophageal mucosa. J Gastroenterol 2003;38:14-22.
22. Eda A, Osawa H, Yanaka I, et al. Expression of homeobox gene CDX2 precedes that of CDX1 during the progression of intestinal metaplasia. J Gastroenterol 2002;37:94-100.
23. Osawa H, Kita H, Satoh K, et al. Aberrant expression of CDX2 in the metaplastic epithelium and inflammatory mucosa of the gallbladder. Am J Surg Pathol 2004;28:1253-1254.
24. Phillips RW, Frierson Jr HF, Moskaluk CA. Cdx2 as a marker of epithelial intestinal differentiation in the esophagus. Am J Surg Pathol 2003;27:1442-1447.
25. Minervini MI, Demetris AJ, Lee RG, et al. Utilization of hepatocyte-specific antibody in the immunocytochemical evaluation of liver tumors. Mod Pathol 1997;10:686-692.
26. Wennerberg AE, Nalesnik MA, Coleman WB. Hepatocyte paraffin 1: a monoclonal antibody that reacts with hepatocytes and can be used for differential diagnosis of hepatic tumors. Am J Pathol 1993;143:1050-1054.
27. Zimmerman RL, Burke MA, Young NA, et al. Diagnostic value of hepatocyte paraffin 1 antibody to discriminate hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration biopsies of the liver. Cancer 2001;93:288-291.
28. Chu PG, Jiang Z, Weiss LM. Hepatocyte antigen as a marker of intestinal metaplasia. Am J Surg Pathol 2003;27:952-959.
29. Fan Z, Li J, Dong B, et al. Expression of Cdx2 and hepatocyte antigen in gastric carcinoma: correlation with histologic type and implications for prognosis. Clin Cancer Res 2005;11:6162-6170.
30. Epstein JI, Amin MB, Reuter VE. Bladder Biopsy Interpretation. Lippincott Williams & Wilkins: Philadelphia, 2004.
31. Cheng L, Nagabhushan M, Pretlow TP, et al. Expression of E-cadherin in primary and metastatic prostate cancer. Am J Pathol 1996;148:1375-1380.
32. Cheng L, Pan CX, Zhang JT, et al. Loss of 14-3-3sigma in prostate cancer and its precursors. Clin Cancer Res 2004;10:3064-3068.
33. Zeng G, Hu Z, Kinch MS, et al. High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. Am J Pathol 2003;163:2271-2276.
34. Kende AI, Carr NJ, Sobin LH. Expression of cytokeratin 7 and 20 in carcinomas of the gastrointestinal tract. Histopathology 2003;42:137-140.
35. Mallofre C, Castillo M, Morente V, et al. Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia. Mod Pathol 2003;16:187-191.
36. Emerson RE, Cheng L. Immunohistochemical markers in the evaluation of tumors of the urinary bladder: a review. Anal Quant Cytol Histol 2005;27:301-316.
37. Jiang J, Ulbright TM, Younger C, et al. Cytokeratin 7 and cytokeratin 20 in primary urinary bladder carcinoma and matched lymph node metastasis. Arch Pathol Lab Med 2001;125:921-923.
38. Chu PG, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol 2000;13:962-972.
39. Moll R, Lowe A, Laufer J, et al. Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am J Pathol 1992;140:427-447.
40. Fan Z, van de Rijn MKM, Rouse RV. Hep par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections. Mod Pathol 2003;16:137-144.
41. Kakar S, Muir T, Murphy L, et al. Immunoreactivity of Hep Par 1 in hepatic and extrahepatic tumors and its correlation with albumin in situ hybridization in hepatocellular carcinoma. Am J Clin Pathol 2003;119:361-366.
42. Grignon DJ, Ro JY, Ayala AG, et al. Primary adenocarcinoma of the urinary bladder. A clinicopathologic analysis of 72 cases. Cancer 1991;67:2165-2172.
43. Corica FA, Husmann DA, Churchill BM, et al. Intestinal metaplasia is not a strong risk factor for bladder cancer: study of 53 cases with long-term follow-up. Urology 1997;50:427-431.
44. Silberg DG, Sullivan J, Kang E, et al. Cdx2 ectopic expression induces gastric intestinal metaplasia in transgenic mice. Gastroenterology 2002;122:689-696.
45. Mutoh H, Sakurai S, Satoh Y, et al. Cdx1 induced intestinal metaplasia in the transgenic mouse stomach: comparative study with Cdx2 transgenic mice. Gut 2004;53:1416-1423.
46. Mutoh H, Sakurai S, Satoh K, et al. Development of gastric carcinoma from intestinal metaplasia in Cdx2-transgenic mice. Cancer Res 2004;64:7740-7747.
47. Mostofi FK. Potentialities of bladder epithelium. J Urol 1954;71:705-714.